Literature DB >> 27712122

The relationship between circulating visfatin/nicotinamide phosphoribosyltransferase, obesity, inflammation and lipids profile in elderly population, determined by structural equation modeling.

Aleksander J Owczarek1, Magdalena Olszanecka-Glinianowicz2, Piotr Kocełak2, Maria Bożentowicz-Wikarek3, Aniceta Brzozowska2, Małgorzata Mossakowska4, Monika Puzianowska-Kuźnicka5,6, Tomasz Grodzicki7, Andrzej Więcek8, Jerzy Chudek3.   

Abstract

BACKGROUND: The available literature suggests that circulating visfatin/Nicotinamide Phosphoribosyltransferase (NAMPT) level variability in humans is related to obesity, insulin resistance, inflammation, and lipid profile. The aim of the study was to assess the relationship between circulating visfatin/NAMPT, obesity, insulin resistance, inflammation, and lipid profile in a large population-based, elderly cohort, applying structural equation modeling.
MATERIALS AND METHODS: The analysis included 2983 elderly participants of the PolSenior study with assessed total blood count, fasting concentrations of lipids, glucose, insulin, hs-CRP, interleukin-6, and visfatin/NAMPT (by ELISA), and calculated HOMA-IR.
RESULTS: The circulating visfatin/NAMPT levels were higher in obese compared to normal weight subjects, in those with hs-CRP above 3 mg/L, with low serum HDL cholesterol, and in insulin resistant subjects. Based on results of the exploratory factor analysis, a baseline model of mutual relationship between four latent and measured variables was created and a final model was developed by maintaining only two significant categories. The important variables for 'latent inflammation' proved to be hs-CRP and IL-6 serum levels. In the case of 'nutritional status', important variables were BMI, waist circumference, and to a lesser extent insulin resistance. Additionally, the residual correlation between those two constructs was also statistically significant.
CONCLUSION: The structural equation modeling provided support for the existence of a link between nutritional status, inflammation and circulating visfatin/NAMPT level. This indicates that circulating visfatin/NAMPT can be considered as a novel surrogate marker of systemic inflammation associated with fat depot, especially visceral, in the elderly population.

Entities:  

Keywords:  Elderly; inflammation; obesity; visfatin/nicotinamide phosphoribosyltransferase

Mesh:

Substances:

Year:  2016        PMID: 27712122     DOI: 10.1080/00365513.2016.1230884

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  5 in total

1.  The relation of visfatin with nausea and vomiting in the pregnancy.

Authors:  Farnaz Jahani; Zohre Khazaei; Mitra Moodi; Asghar Zarban; Fatemeh Salmani; Zoya Tahergorabi
Journal:  J Res Med Sci       Date:  2020-08-24       Impact factor: 1.852

2.  Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial.

Authors:  Liping Yang; Yun Qiu; Wenhua Ling; Zhaomin Liu; Lili Yang; Changyi Wang; Xiaolin Peng; Li Wang; Jianying Chen
Journal:  Eur J Nutr       Date:  2020-09-15       Impact factor: 5.614

3.  Aerobic and resistance exercise training reverses age-dependent decline in NAD+ salvage capacity in human skeletal muscle.

Authors:  Roldan M de Guia; Marianne Agerholm; Thomas S Nielsen; Leslie A Consitt; Ditte Søgaard; Jørn W Helge; Steen Larsen; Josef Brandauer; Joseph A Houmard; Jonas T Treebak
Journal:  Physiol Rep       Date:  2019-07

4.  Diagnostic Significance of Plasma Levels of Novel Adipokines in Patients With Symptomatic Intra- and Extracranial Atherosclerotic Stenosis.

Authors:  Fang Yu; Xiaoqing Zhou; Zhibin Li; Xianjing Feng; Di Liao; Zeyu Liu; Qin Huang; Xi Li; Qidong Yang; Bo Xiao; Jian Xia
Journal:  Front Neurol       Date:  2019-11-19       Impact factor: 4.003

5.  Visfatin is regulated by interleukin‑6 and affected by the PPAR‑γ pathway in BeWo cells.

Authors:  Yanhong Zhang; Yan Huo; Wenhui He; Suxin Liu; Hongyan Li; Li Li
Journal:  Mol Med Rep       Date:  2018-11-20       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.